Compound News and Research

RSS

OPKO Health signs agreement with Schering-Plough to acquire assets relating to NK-1 program

OPKO Health, Inc. today announced that it has entered into a definitive agreement with Schering-Plough Corporation to acquire assets relating to Schering’s neurokinin-1 (NK-1) receptor antagonist program. Rolapitant, the lead product, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications.

14 Oct 2009

Researchers test Orizon Research's ALKA-V6 silicon-based compound

Researchers at Texas State University-San Marcos have completed initial testing of a cancer chemotherapeutic and anti-retroviral compound with promising results.

14 Oct 2009

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Metabolic Solutions Development Company (MSDC) announced today that it has received a $100,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF) to support the evaluation of PPAR-sparing insulin sensitizers as a potential treatment for Alzheimer's disease.

14 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Sequella receives Phase 1 SBIR grant for developing SQ641

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.

13 Oct 2009

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.

13 Oct 2009

AACR to host its first Frontiers in Basic Cancer Research Meeting

The American Association for Cancer Research will host its first Frontiers in Basic Cancer Research Meeting in Boston from Oct. 8-11, 2009. The meeting is expected to draw nearly 500 leading scientists to present on high-profile topics like epigenetics, metastasis and systems biology, and create synergies among the many subfields of basic science.

12 Oct 2009

Wal-Mart Stores to offer Tamiflu oral suspension in liquid form for children and elderly

Wal-Mart Stores, Inc. announced today that more than 4,000 Walmart and Sam's Club pharmacies nationwide will address the national shortage of Tamiflu® oral suspension by converting the capsule to liquid form.

12 Oct 2009

TargetEx to be the coordinator for CancerGrid consortium

TargetEx llc, Budapest announced today that the Research Directorate General of the Commission of the European Communities approved the transfer of the coordinator responsibilities of the European Cancer Research Consortium (CancerGrid) to TargetEx.

9 Oct 2009

New soy germ-based ingredient improves menopausal symptoms

SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women.

9 Oct 2009

Angiochem to announce clinical study results of ANG1005 drug

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that clinical data for its lead drug candidate, ANG1005, for the treatment of brain cancers, as well as data showing how compounds from Angiochem’s Engineered Peptide Compounds (EPiC) platform are capable of crossing the blood-brain barrier will be highlighted at the Society for Neuroscience Annual Meeting in Chicago on October 17-21, 2009.

8 Oct 2009

Xcelience's Xcelodose 120S precision powder micro-dosing system accelerates drug development

Xcelience, a leader in early development services, recognizes that providing access to a third, dedicated Xcelodose® 120S precision powder micro-dosing system in the experimental area enables clients to accelerate drug development with preliminary compound evaluation, earlier go/ no-go decisions and flexible options for experimental studies.

8 Oct 2009

Paratek Pharmaceuticals and Novartis to collaborate in PTK 0796 broad-spectrum antibiotic development

Paratek Pharmaceuticals, Inc. announced today that it has entered into an exclusive worldwide collaborative development, manufacturing and commercialization license agreement with Novartis for Paratek's lead broad-spectrum antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC) in Phase 3 clinical trials.

8 Oct 2009

Dominion Diagnostics enhances laboratory testing procedure for chronic opioid pharmacotherapy

Only a short time after introducing its newly developed and validated tapentadol assay, Dominion Diagnostics (Dominion) is pleased to announce an important enhancement to another clinical laboratory test.

8 Oct 2009

Mimetogen Pharmaceuticals completes its equity financing

Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately held drug development company announced today that it has successfully completed an equity financing, co-led by Boston-based VIMAC Milestone Medica Fund and Montréal-based iNovia Capital.

8 Oct 2009

Rite Aid pharmacists provide regular seasonal flu shots to help prevent flu

Patients have more options than ever this year at their local Rite Aid pharmacy to help prevent the flu. More than 2,000 Rite Aid certified immunizing pharmacists in more than 1,500 Rite Aid stores have been giving regular seasonal flu shots and will continue to do so throughout the flu season.

8 Oct 2009

Global pharmaceutical market to grow by 4 - 6 percent: IMS Health

IMS Health reported today that the value of the global pharmaceutical market in 2010 is expected to grow 4 - 6 percent on a constant-dollar basis, exceeding $825 billion, driven by stronger near-term growth in the U.S. market.

8 Oct 2009

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company’s lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.

7 Oct 2009

Galapagos receives EUR 500,000 cash payment from GSK

Galapagos NV (Euronext: GLPG) announced today that it has reached the first milestone in its antibacterials and antivirals alliance with GlaxoSmithKline (GSK). For achieving this milestone, Galapagos receives a EUR 500,000 cash payment from GSK.

7 Oct 2009

Aeolus Pharmaceuticals raises $1.65 million from existing institutional shareholders

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the “Units”), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.

7 Oct 2009